source
- Analysts zero in on three Bristol Myers programs as company gears up for multiple data readouts through 2026Analysts are closely watching Bristol Myers Squibb's pipeline, focusing on three key programs that could drive growth in the coming years. Wall Street expects a flurry of data readouts, with at le…
- Lilly’s obesity pill Foundayo sees slower early uptake than Novo’s, with only about 20,000 users in first 20 daysEli Lilly launched its obesity medication Foundayo recently, and the company reported that roughly 20,000 patients have started the treatment within the first 20 days. CEO David Ricks said this ea…